{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:38:06Z","timestamp":1789025886546,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007043","name":"Lymphoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T13:18:49Z","timestamp":1531919929000},"page":"306-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Peripheral T-cell lymphoma \u2013 are we making progress?"],"prefix":"10.1016","volume":"31","author":[{"given":"Niloufer","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neval","family":"Ozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2018.07.010_bib1","series-title":"Classification of tumours of haematopoietic and lymphoid tissues","year":"2017"},{"issue":"19","key":"10.1016\/j.beha.2018.07.010_bib2","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.07.010_bib3","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.07.010_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","article-title":"Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas","volume":"33","author":"Huang","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.010_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2018.07.010_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.010_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.beha.2018.07.010_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2018.07.010_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.07.010_bib10","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2018.07.010_bib11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.010_bib12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","article-title":"Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing","volume":"117","author":"Feldman","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.07.010_bib13","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.010_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.beha.2018.07.010_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0b013e318282d01e","article-title":"Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis","volume":"37","author":"Karai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.010_bib16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Canc Cell"},{"issue":"3","key":"10.1016\/j.beha.2018.07.010_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2017.4510","article-title":"Breast implants and the risk of anaplastic large-cell lymphoma in the breast","volume":"4","author":"de Boer","year":"2018","journal-title":"JAMA oncology"},{"issue":"2","key":"10.1016\/j.beha.2018.07.010_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma","volume":"20","author":"Streubel","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2018.07.010_bib19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/leu.2008.320","article-title":"Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas","volume":"23","author":"Feldman","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2018.07.010_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3324\/haematol.2015.139253","article-title":"Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma","volume":"101","author":"Yoo","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2018.07.010_bib21","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.010_bib22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.LAB.0000090157.13040.58","article-title":"High frequency of genetic aberrations in enteropathy-type T-cell lymphoma","volume":"83","author":"Baumgartner","year":"2003","journal-title":"Lab. Invest. J. Tech. Meth. Pathol."},{"issue":"11","key":"10.1016\/j.beha.2018.07.010_bib23","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/leu.2016.178","article-title":"Mutations in the JAK\/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas","volume":"30","author":"Nicolae","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2018.07.010_bib24","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1053\/j.gastro.2007.03.036","article-title":"Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes","volume":"132","author":"Deleeuw","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beha.2018.07.010_bib25","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.beha.2018.07.010_bib26","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood-2018-01-830968","article-title":"Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract","volume":"131","author":"Sharma","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.010_bib27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann OncolOffic J Eur Soc Med Oncol"},{"key":"10.1016\/j.beha.2018.07.010_bib28","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.010_bib29","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2018.07.010_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.010_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.beha.2018.07.010_bib32","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front autologous stem-cell transplantation in peripheral t-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.010_bib33","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"issue":"22","key":"10.1016\/j.beha.2018.07.010_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V128.22.186.186","article-title":"Interim PET evaluation by deauville criteria is an effective risk stratification tool in PTCL","volume":"128","author":"Mehta-Shah","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2018.07.010_bib35","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","volume":"124","author":"Ansell","year":"2014","journal-title":"Brentuximab vedotin Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2018.07.010_bib36","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2018.36.15_suppl.7509","article-title":"Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials","volume":"36","author":"Ghione","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.010_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2018.07.010_bib38","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/jco.2015.33.15_suppl.8521","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: activity in T-cell lymphoma","volume":"33","author":"Mehta-Shah","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2018.07.010_bib39","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V128.22.2991.2991","article-title":"A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory t-cell lymphomas","volume":"128","author":"Mehta-Shah","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.010_bib40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.07.010_bib41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood.V130.Suppl_1.819.819","article-title":"In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, in combination with romidepsin or bortezomib in relapsed\/refractory t-cell lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2018.07.010_bib42","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2018.36.15_suppl.7510","article-title":"Tenalisib, a dual PI3K \u03b4\/\u03b3 inhibitor: safety and efficacy results from an on-going phase I\/Ib study in relapsed\/refractory T-cell lymphoma","volume":"36","author":"Oki","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.beha.2018.07.010_bib43","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1200\/JCO.2018.36.15_suppl.7511","article-title":"The dual SYK\/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed\/refractory B- and T-cell non-Hodgkin lymphoma (NHL)","volume":"36","author":"Hamlin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.07.010_bib44","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2018.07.010_bib45","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2018.07.010_bib46","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2018.07.010_bib47","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult t-cell leukemia\u2013lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beha.2018.07.010_bib48","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.010_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.beha.2018.07.010_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral t-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the bel-CHOP phase 1 trial","volume":"126","author":"Johnston","year":"2015","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.beha.2018.07.010_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/hon.2439_190","article-title":"Phase I\/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: phase I results from the T-cell consortium","volume":"35","author":"Lunning","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.07.010_bib52","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V130.Suppl_1.818.818","article-title":"Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral t-cell lymphoma (PTCL): a phase 1 dose-escalation study","volume":"130","author":"Shustov","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.07.010_bib53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.010_bib54","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol Offic J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.010_bib55","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"29","author":"Townsend","year":"2016","journal-title":"Canc Cell"},{"issue":"1","key":"10.1016\/j.beha.2018.07.010_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.010_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.010_bib58","first-page":"168","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.beha.2018.07.010_bib59","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral t-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.010_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.010_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.beha.2018.07.010_bib62","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:22:40Z","timestamp":1661631760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300513"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.010","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T-cell lymphoma \u2013 are we making progress?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}